A randomized placebo-controlled trial tested three concentrations of smoked cannabis (high THC, high CBD, THC+CBD) against placebo in military veterans with PTSD. Over three weeks, all groups including placebo showed significant improvements in PTSD symptom severity, but none of the active cannabis concentrations outperformed placebo statistically. The treatments were generally well tolerated. This preliminary trial did not find evidence that smoked cannabis is more effective than placebo for PTSD symptoms in the short term, highlighting the need for further well-powered studies.
A new liquid chromatography-tandem mass spectrometry (LC-MS/MS) method measures psilocybin and psilocin in the mushroom species Psilocybe cubensis. Five strains—Blue Meanie, Creeper, B-Plus, Texas Yellow, and Thai Cubensis—were analyzed. The method detects psilocybin at 300 ng/g and psilocin at 30 ng/g of mushroom, with accuracy and precision errors under 6%. From most to least potent, average total psilocybin and psilocin concentrations were 1.36% (Creeper), 1.221% (Blue Meanie), 1.134% (B+), 1.103% (Texas Yellow), and 0.879% (Thai Cubensis) by weight. Results were comparable between two laboratories, and homogenizing multiple mushrooms together improved precision.